September 6, 1985
The company's board of directors declared a dividend of one stock purchase right on each of the company's 144 million common shares outstanding. The right allows holders to purchase a share of common stock at an exercise price of $100 if any purchaser acquires 20% or more of Dart & Kraft's common shares or announces a tender offer for 30% or more of the shares.
November 20, 1999 |
NeoTherapeutics Inc. completed a $10-million private placement of 845,594 common shares at $11.83 a share with two institutional investors. The company will use the funds to expand its clinical trial program for Neotrofin, a potential treatment for Alzheimer's disease. In a press release Friday, the bio-pharmaceutical company said the investors also received five-year warrants to acquire 126,839 common shares at the exercise price of $14.24.
July 26, 1986 |
Capping a run-up of nearly $62 in the past three months, Viratek on Friday declared a 2-for-1 stock split to lure more investors by making its suddenly high-priced common shares more affordable. Several analysts have said that they believe the rapid price increase--Viratek's common shares closed Friday at $96.50 per share--has been fueled by investors betting that its anti-viral drug, Virazole, will be approved as a treatment for the deadly acquired immune deficiency syndrome, or AIDS.
December 20, 1996
Furon Co. said Thursday it has extended its offer for Medex Inc.'s outstanding common shares to Jan. 2. The tender offer was scheduled to expire Thursday. Furon offered to buy Medex common shares and share rights at $23.50 each. More than 5.1 million shares of Medex common stock, or 90% of those outstanding, had been tendered and not withdrawn. Medex of Hilliard, Ohio, makes polymer-based critical-care products and infusion systems for medical and surgical applications.
December 20, 1988
Syncor International, a Chatsworth provider of specialized pharmaceuticals, said it plans to buy back up to 500,000 of its common shares in periodic open-market purchases. The buyback represents about 4.8% of Syncor's 10.5 million total common shares outstanding. The stock closed Monday at $4.75 in over-the-counter trading; at that price, the buyback would cost Syncor $2.4 million.